5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More

The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Bio-Techne Corporation TECH

• Deutsche Bank initiated coverage on Bio-Techne with a Buy rating and announced a price target of $100. The company’s stock has a 52-week low of $68.00 .
• RSI Value: 18.25
• TECH Price Action: Shares of Bio-Techne fell 0.2% to settle at $86.81 on Wednesday, and gained 0.7% in after-hours trading.

Mirati Therapeutics, Inc. MRTX

• The FDA granted accelerated approval to Mirati Therapeutics Krazati (adagrasib), a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). The company’s stock has a 52-week low of $32.96.
• RSI Value: 29.65
• MRTX Price Action: Shares of Mirati Therapeutics gained 4.2% to close at $43.73 on Wednesday, and lost 0.8% in the after-hours trading session.

Corcept Therapeutics Incorporated CORT

• HC Wainwright & Co. maintained Corcept Therapeutics with a Buy and lowered the price target from $33 to $30. The company’s stock has a 52-week low of $16.47.
• RSI Value: 26.82
• CORT Price Action: Shares of Corcept Therapeutics dropped 1% to close at $20.65 on Wednesday, and gained 0.9% in the after-hours trading session.

Cytek Biosciences, Inc. CTKB

• Cytek Biosciences, last month, reported weaker-than-expected results for its third quarter. The company’s 52-week low is $7.38.
• RSI Value: 29.91
• CTKB Price Action: Shares of Cytek Biosciences gained 1.2% to close at $11.46 on Wednesday.

OPKO Health, Inc. OPK

• OPKO Health, last month, reported worse-than-expected Q3 EPS and sales results. The company has a 52-week low of $1.28.
• RSI Value: 29.93
• OPK Price Action: Shares of OPKO Health dropped 1.5% to settle at $1.29 on Wednesday, and added 2.3% in the after-hours trading session.